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The seeds of Ginkgo biloba are commonly eaten in Japan, Korea and China, but it is important to know
that they can be responsible for poisoning, especially in young children. Poisoning due to Ginkgo biloba
seeds must also be considered as a possible clinical event in European countries, where Asian cuisine has
recently become popular. This paper reports the case of a 23-months-old previously healthy male child
who experienced two afebrile tonic-clonic seizures after the consumption of an unknown amount of
Ginkgo seeds. The poisoning was identiﬁed by searching both in blood and urine for 4’-O-methyl-
pyridoxine (MPN) as a speciﬁc biomarker for ginkgo poisoning, using an optimized and validated HPLC
method with ﬂuorimetric detection. The MPN concentrations in serum were 16.5 and 6.2 ng mL−1 14 and
20 hours after the exposure, respectively, while the urine concentration was below the limit of detection
(1.35 ng mL−1). The involvement of ginkgo seeds in the described poisoning was conﬁrmed by searching
ginkgolide terpene lactones in urine, where the ratio between excreted ginkgolide A : B : C was 1 : 40 : 2.
The analytical data obtained by looking for biomarkers in serum and urine demonstrate that even low
values of MPN/ginkgolide concentration can be responsible for convulsions and other adverse eﬀects.
Introduction
Ginkgo biloba (commonly known as ginkgo or Maindenhair
tree) is an ancient tree with distinctive fan-shaped leaves,
belonging to the family of Ginkgoaceae. Leaves and seeds are
the parts most usually consumed, both as food (roasted or
cooked seeds) and as extracts in food supplements and tra-
ditional medicines. The leaf extract is widely used in Europe as
a traditional drug to improve the symptoms of early-stage Alz-
heimer’s disease, vascular dementia, peripheral claudication
and tinnitus of vascular origin.1–4 The adverse eﬀects of
Ginkgo biloba preparations containing leaves are numerous;
approximately 30% of these cases are due to interaction with
therapeutic drugs, including acetyl salicylic acid, ibuprofen
and warfarin.5
The haemorrhagic complications, due to poisoning or inter-
action with prescription drugs, are probably due to the antipla-
telet activity of ginkgolides, and in particular of Ginkgolide B.6
Ginkgo biloba seeds are commonly eaten in Japan, Korea
and China for their nutritive value, but it is important to know
that they can be responsible for poisoning, especially in young
children.7,8 Even though they are infrequent, clinical cases of
ginkgo seed poisoning show severe symptoms, including tonic
or clonic convulsion, vomiting, irritability and loss of
consciousness.7–9
Poisoning by ginkgo seeds is due to the neurotoxic com-
pound 4′-O-methylpyridoxine (MPN), which is chemically
related to vitamin B6 and interfere with its biosynthesis,
metabolism and function. The chemical structures of MPN
and vitamin B6 are reported in Fig. 1.
Ginkgo biloba seeds contain MPN at concentrations ranging
between 170 and 400 μg g−1 of raw seeds.10–13 The toxin is rela-
tively heat-resistant so that cooking or other treatments only
partially inactivate it.14–16
Kajiyama & Fujii (2002)7 described a case of poisoning in a
2-year-old girl who showed unexplained convulsions with
vomiting, diarrhoea and irritability. The event was associated
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with the ingestion of 50 to 60 roasted ginkgo seeds, as reported
by the parents. Similarly, a case of poisoning was described in
another 2-year-old girl who had eaten about 50 ginkgo seeds
4 hours before the onset of symptoms8 and a case of poisoning
with ginkgo nuts was observed in a healthy 36-year-old
woman, who consumed 70–80 seeds cooked in a microwave
oven.9 The pathophysiologic mechanisms responsible for con-
vulsions related to ginkgo poisoning are not fully understood.
As known from in vivo studies, 4′-O-methylpyridoxine (MPN)
competes with vitamin B6, which is a cofactor of glutamate
decarboxylase; as a consequence, MPN indirectly inhibits the
activity of this enzyme resulting in a decrease of the γ-amino-
butyric acid (GABA) level in brain, which predisposes to
convulsions.9,17,18
The study reported in this paper describes a case of ginkgo
poisoning which occurred in Switzerland in a 23-months-old
boy, where the association with the ingestion of ginkgo seeds
was confirmed by measuring biomarkers both in blood and
urine.
Materials
Clinical data
A 23-months-old previously healthy male child of Asian origin
experienced two afebrile tonic-clonic seizures for 15–30
seconds. He had a 2 hour period of vomiting and somnolence.
The parents reported that the child ingested an unknown
amount of Ginkgo seeds 10 hours before the beginning of
symptoms. The subsequent clinical course was uneventful
with full recover. Blood samples were taken 14 and 20 hours
after the ingestion of seeds, while urine was collected only
14 hours after intake. No ethics committee/institutional review
board approval was necessary for the analyses performed in
this case, since they were requested to identify poisoning
source. Informed consent to the publication of this case was
obtained from the patient’s family.
Purified standards
4′-O-methylpyridoxine (MPN). The toxin 4′-O-methylpyridoxine
was not commercially available at the time of the study, so that
we synthesized it ourselves according to the method described
by Harris (1940).19 A mixture of 2-methyl-3-hydroxy-4,5-
dihydroxymethylpyridine hydrochloride (10.25 g, 50.0 mmol)
and sodium methoxide (2.71 g, 50.0 mmol) in methanol
(80 mL) was heated in a bomb tube at 130 °C for 12 h. The
solvent was evaporated oﬀ and the residue treated with
acetone and filtered to remove the sodium chloride. The
organic solution was concentrated to give an oily residue,
which was chromatographed on silica gel. Elution with ethyl
acetate–methanol (80 : 20, v/v) yielded 5.2 g (56.5%) of
2-methyl-3-hydroxy-4-methoxymethyl-5-hydroxymethylpyridine
as an orange oil. The compound was dissolved in ethanol
(20 mL) and 2.6 M ethanolic HCl (15 mL) was added while stir-
ring. The suspension was heated at reflux and, after cooling to
Fig. 1 Chemical structures of 4’-O-methylpyridoxine, pyridoxine (vitamin B6), ginkgolides and bilobalide.
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0 °C, filtered to give 4.1 g (37.5%) of the compound as a white
solid; the final product was chemically characterized to
confirm the identity, as described in Results and discussion.
Ginkgolides. Reference standards for (−)-bilobalide and
ginkgolides A, B, C were kindly supplied by PhytoLab (Vesten-
bergsgreuth, Germany).
Reagents. The reagents used in the study were: acetone for
HPLC (Farmitalia Carlo Erba, Milano, Italia); acetonitrile,
methanol, water for HPLC and 37% hydrochloric acid (VWR
International, Fontenay-sous-Bois, France); absolute ethanol
for analysis (Merck KGaA, Darmstadt, Germany); ethyl acetate
for HPLC 99.9%, L-ascorbic acid, formic acid ≥98%, and hepta-
fluorobutyric acid ≥99% (Sigma-Aldrich, Steinheim, Germany);
ethylenediaminetetraacetic acid (EDTA, Bio-Rad Laboratories,
Hercules, California, USA).
Methods
Quantification of 4′-O-methylpyridoxine (MPN) in serum
Preparation of standard solutions and serum sample. Ali-
quots of 1 mg of MPN were solubilised in 10 mL of 0.1 M HCl,
the final concentration being 100 μg mL−1. Further standards
of 1 and 0.1 μg mL−1 (prepared by dilution in 0.1 M HCl) were
added to a healthy volunteer’s serum present in our seroteque
(“blank” sample) to obtain the final concentrations of 4.5, 7.2,
13.5, and 27 ng mL−1 of MPN, which were used to prepare the
test for linear regression. Aliquots of 500 μL of these solutions
or of the blank/patient’s serum were added to 500 μL of
acetone; the resulting solutions were thoroughly vortexed, and
centrifuged at 2500 rpm for 5 minutes (Hermle Labortechnik
GmbH, Wehingen, Germany). The supernatants were filtered
through a 0.45 μm syringe filter (VWR International, Fontenay-
sous-Bois, France) and injected into the HPLC.
Chromatographic conditions. A HPLC method combined
with fluorimetric detection was used for the rapid separation
and quantification of 4′-O-methylpyridoxine (MPN) in the
patient’s serum. The equipment consisted of an Intelligent
PU-880 pump (Jasco, Tokyo, Japan), a fluorescence Detector
FP-1520 (Jasco, Tokyo, Japan), a sample injection valve Rheo-
dyne 7725 with 20 μL loop (Cotati, California, USA), a column
of Inertsil ODS-2, 125 × 4.6 mm, particle size 5 μm (GL
Sciences Inc., Tokyo, Japan). ChromNAV software (Jasco,
Tokyo, Japan) was used for integration. The analysis was per-
formed by isocratic elution at a flow rate of 1 mL min−1 with
the mobile phase: 0.1% heptafluorobutyric acid in water, and
acetonitrile, 90 : 10 (v/v). The column was heated at 40 °C, and
the fluorescence detector was set at 290/400 nm (λex/λem).
Method validation. The HPLC method has been validated
as described in Results. The suitability of the chromatographic
system was daily checked by using the ChromNAV software
(Jasco, Tokyo, Japan).
Detection of ginkgolides and bilobalide in urine
Preparation of standard solutions. Aliquots of 1 mg of each
standard (ginkgolides A, B, C and bilobalide) were dissolved in
10 mL of water to a final concentration of 100 μg mL−1.
Dilutions were carried out in order to obtain a final mixture
containing 10 µg mL−1 of each standard.
Sample preparation. The urine sample was prepared accord-
ing to Dew et al. (2014).20 It was thawed at room temperature
immediately before extraction, placed in an ultrasonic water
bath (5 min), then vortexed (30 s) to ensure homogeneity. The
sample was extracted in triplicate. Each 200 µL aliquot of urine
was combined with 20 µL of an aqueous mixture of ascorbic
acid (1% w/v) and EDTA (0.1% w/v), 100 µL of ethanol and
1 mL of ethyl acetate in a 1.5 mL centrifuge tube. The solution
was vortexed (30 s), placed in an ultrasonic water bath (5 min)
and vortexed again to extract soluble compounds. The tubes
were centrifuged (Hermle Labortechnik GmbH, Wehingen,
Germany) at 17 000 rpm for 10 min at 8 °C and the upper layer
was removed. A second 1 mL aliquot of ethyl acetate was
added to the pellet, and the extraction procedure repeated. All
extracts were dried under nitrogen at room temperature and
frozen at – 20 °C. On the day of analysis, the second extracts
were solubilized in 70 µL of ethanol, vortexed (30 s), placed in
an ultrasonic water bath (5 min) and vortexed again. A 50 µL
aliquot of this solution was combined with the corresponding
first dried extract, which was similarly vortexed and sonicated.
A 50 µL aliquot of ascorbic acid solution (0.2%, w/v) was
added to the combined extract, which was then vortexed and
centrifuged at 17 000 rpm at 8 °C for 10 min. The supernatant
was placed in a HPLC vial, which was capped and kept at 8 °C
until the analysis.
Chromatographic conditions. A HPLC-MS method was
applied for the rapid separation of ginkgolides and bilobalide
in urine. The equipment included a HPLC Surveyor MS Pump
Plus coupled to an ion trap mass spectrometer LCQ Deca XP
MAX (Thermo Electron Co, San Jose, CA, USA), a column
Kinetex 2.6 µm PFP, 100 A, 100 × 2.1 mm (Phenomenex, Tor-
rance, California, USA), and a Surveyor Autosampler Plus
(Thermo Electron Co, San Jose, CA, USA). The software Excali-
bur® Release 2.0 SR2 (Thermo Electron, San Jose, CA, USA)
was used for integration. The analysis was performed accord-
ing to Dew et al. (2014),20 using a gradient elution at a flow
rate of 0.3 mL min−1; the mobile phases were: (A) water–
methanol–formic acid, 94.9 : 5 : 0.1 (v/v/v), and (B) methanol–
water–formic acid 95 : 4.9 : 0.1 (v/v/v). The gradient elution was
set up as shown in Table 1. The autosampler and column oven
temperatures were set at 8 °C and 35 °C, respectively, and the
Table 1 Elution gradient used for the analysis of ginkgolides and bilo-
balide in urine
Time (min) Phase A (%) Phase B (%)
0 92 8
5 92 8
20 60 40
22 10 90
24 10 90
26 92 8
34 92 8
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injection volume was 20 µL. MS analysis was performed in
negative ionization mode. The capillary temperature was
300 °C, the nebulized gas was nitrogen, sheath gas flow was
50 arb and sweep gas flow was 10 arb.
Results and discussion
Consumption of Ginkgo biloba seeds is quite common in Asian
cuisine and in Oriental countries with a normally rather low
risk. Traditionally, the seeds are roasted or boiled to reduce
the activity of the neurotoxin, 4′-O-methylpyridoxine. Because
of the rapid diﬀusion of oriental cuisine in other countries,
the risk could be greater there from the unsuitable intake of
ginkgo seeds. Both authorities and the population should be
carefully informed of this possibility. To our knowledge, the
case of gingko seed poisoning described in this paper is the
first to occur in Europe.
The objectives of this work were: (1) to confirm the sus-
pected intoxication by Ginkgo biloba seeds; (2) to develop accu-
rate methods of measuring biomarkers useful in identifying
similar events in the future. In fact, because of the severity of
symptoms and the prevalent involvement of children, a clear
methodological approach is necessary to allow rapid diagnosis
and treatment.
In this case, a 23-months-old male child was brought to the
emergency department after tonic-clonic seizures in both
arms, and after discussion with the parents we hypothesized
that the cause was intoxication by Ginkgo biloba seeds, so that
serum and urine were collected and immediately sent for bio-
marker analysis.
On the basis of the paper by Hori et al. (2004),10 a HPLC
method for detection of the neurotoxin MPN was set up, with
some modifications as described in Methods. Because purified
MPN was not available, we synthesized it, as described in
Materials and methods. The final product was checked for
quality and purity. Purity of 4′-O-methyl pyridoxine was 90%,
the remaining 10% being the pyridoxine used as a starting
reagent in the synthetic procedure. Since pyridoxine did not
interfere with the analysis, this standard was used as a refer-
ence compound for quantification, and a correction factor for
purity was applied.
The identity of synthesized MPN was confirmed by its
melting point of 179–180 °C, and NMR analysis 1H NMR
(DMSO-d6) δ 10.90 (bs, 1 H) 8.13 (s, 1 H), 5.75 (bs, 2 H), 4.68
(s, 2 H), 4.65 (s, 2 H), 3.29 (s, 3 H), 2.63 (s, 3 H). Anal. Calcd for
C9H14ClNO3.
A problem arose during the setting up of the method was the
diﬀerent performance shown by MPN standard in water/buﬀer
solutions, compared to human serum or urine. For this reason
the linear regressions were prepared in human serum/urine.
Validation of the method used for the quantification of
4′-O-methylpyridoxine (MPN) in serum
The method for the quantification of MPN in serum/urine was
validated according to the guidelines described by Peters et al.
(2007),21 for the following parameters: selectivity, linearity,
accuracy, precision and sensitivity (LOD and LOQ). Further-
more, the system suitability test (SST) was performed accord-
ing to the current FDA Guidelines on Bioanalytical Method
Validation.22 Since MPN was undetectable in child’s urine, the
relative validation of method is not reported here.
System suitability test (SST)
The following parameters were calculated: retention factor (K),
separation factor between two neighbouring peaks (α), peak
tailing factor and column eﬃciency (number of theoretical
plates). The analysis was performed in triplicate.
Table 2 shows the results of the SST obtained from the ana-
lysis of the “blank” serum spiked with MPN at the final con-
centration of 30 ng mL−1.
The parameters show that the chromatographic system
used in this assay was highly eﬃcient and suitable for the
quantification of MPN, having retention factor (K) ≥ 2, separ-
ation factor (α) > 1, symmetry factor (SF) ≤ 2.22
Selectivity
The possible interaction between analytes and endogenous
matrix components was investigated by adding standard MPN
to the “blank” serum (final 30 ng mL−1). Peak areas of com-
pounds coeluting with the analytes should be less than 20% of
the peak area of sample at LOQ. As shown in Fig. 2, MPN can
be clearly identified; no peak at the retention times of MPN
had an area exceeding 20% at LOQ values.
Linearity
Standard solutions (1 and 0.1 μg mL−1) were added to a
“blank” serum to have final concentration of 5, 8, 15 and
30 ng mL−1; these solutions were prepared as described in
“sample preparation” and analysed with three independent
injections.
Linear regression was obtained by plotting the areas of
analyte peaks vs. the nominal concentrations. The calibration
curve equation and the corresponding correlation coeﬃcient
(R2) were calculated taking into account the purity of the stan-
dard (90%). The linear regression, used to calculate MPN con-
centrations in serum is illustrated in Fig. 3. The method was
Table 2 System suitability test for MPN (n = 3)
tR
a (min)
(mean ± SD)
Kb
(mean ± SD)
αc
(mean ± SD)
SFd
(mean ± SD)
Ne
(mean ± SD)
9.76 ± 0.07 2.86 ± 0.08 1.21 ± 0.01 1.01 ± 0.07 1701 ± 292
a tR = Retention time.
b Retention factor (K) = (tR − t0)/t0, where tR and
t0 are retention times of MPN and solvent, respectively.
c Separation
factor (α) = (tR − t0)/(tR1 − t0), where tR and tR1 are retention times of
MPN and a neighboring peak, respectively. d SF (symmetry factor) =
W0.05/2f where W0.05 is width of the peak at 5% height and f the
distance from the peak maximum to the leading edge of the peak, the
distance being measured at a point 5% of the peak height from the
baseline. e N (number of theoretical plates) = 16/(tR/W)
2, where W is the
peak width at its base.
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linear between 4.5 and 27 ng mL−1, as shown by the corre-
lation coeﬃcient (R2) higher than 0.99. The linear regression
equation was y = 13 872x + 23 918, where y refers to the peak
area and x refers to concentration.
Accuracy and precision
Accuracy and precision were determined spiking “blank”
serum samples with two concentrations of the MPN standard
(0.1 and 1 µg mL−1) in order to have final concentrations at 6
and 25 ng mL−1 (corresponding to actual concentrations of
MPN of 5.4 and 22.5 ng mL−1, respectively).
Accuracy was calculated as the percent of variation between
the experimentally measured means and the nominal values.
Precision was determined by calculating the variation coeﬃ-
cient (RSD%) of the peak areas of five replicates injected in
the same day.
Table 3 shows the results obtained for accuracy and pre-
cision. Being RSD% <15%, the method must be considered
precise, and since the calculated accuracy was always within
±15% of the nominal concentration, the method can be con-
sidered accurate.
Sensitivity (LOD and LOQ)
The sensitivity of the analytical method was evaluated by deter-
mining the limit of detection (LOD) and the limit of quanti-
tation (LOQ). LOD and LOQ were determined spiking “blank”
serum samples with decreasing concentrations of MPN stan-
dard: LOD was established at a signal-to-noise ratio of 3 and
LOQ at a signal-to-noise ratio of 10. The LOQ was based on
data obtained from 5 independent injections.
LOD and LOQ for MPN measured in the “blank” serum
were 1.35 and 4.5 ng mL−1, respectively. The precision at LOQ
was 13.9%, below the acceptable limit of 15%. All values
reported above were suitable for an accurate determination of
MPN in serum samples.
Quantification of 4′-O-methylpyridoxine (MPN) in serum
Fig. 4 illustrates the results of MPN quantification in the
patient’s serum at 14 and 20 hours after eating Ginkgo biloba
seeds (Panels B and C, respectively). Panel A of the same
figure shows the chromatogram of MPN standard solution at
the concentration of 0.1 μg mL−1. The presence of pyridoxine,
as a residue of starting reagent, is clearly evident and was
quantified in 10%. As discussed above, the elution time of this
“impurity” does not interfere with the MPN determination.
MPN concentrations in the child’s serum were 16.53 ± 1.55
and 6.18 ± 0.69 ng mL−1 (m ± SD), at 14 and 20 h from intake,
respectively. MPN was also searched for in urine (data
Fig. 2 Chromatograms of a “blank” serum (left panel) and of a “blank” serum added with a standard solution of 4’-O-methylpyridoxine (MPN) at the
ﬁnal concentration of 30 ng mL−1 (right panel).
Fig. 3 Linear regression in human serum for MPN quantiﬁcation.
Table 3 Accuracy and precision data (n = 5)
Standard
concentration
(ng mL−1)
MPN concentrationa
(ng mL−1) Accuracyb Precisionc
6 5.4 +6.20% 7.36%
25 22.5 +0.07% 7.10%
a Allowing for the 95% purity. b (Mean of calculated values/nominal
value) × 100. c Expressed as relative standard deviation (RSD) of
calculated values (%).
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not shown) but values were below the limit of detection of
1.35 ng mL−1.
Identification of ginkgolide terpene lactones in urine
Since MPN was undetectable in urine, a further confirmation
of exposure to Ginkgo biloba seeds was done by searching gink-
golides and bilobalide in the child’s urine. The use of terpenic
lactones as urinary biomarkers of ginkgo intake has been con-
sidered previously and very recently, interesting results have
been published by Dew and coworkers.20 The chemical struc-
tures of these molecules are illustrated in Fig. 1. The detection
of ginkgolides (A, B, C) and bilobalide was obtained by HPLC
coupled to mass spectrometry. Fig. 5 shows the results
obtained by total ion chromatography (TIC) and the single ion
monitoring (SIM) for the identification of the Ginkgo biloba
biomarkers. Panel A shows the chromatograms associated with
a mixture of standards at the concentration of 10 μg mL−1 for
each analyte. The absence of any interfering signal in the
“blank” urine is shown in panel B and finally, the presence of
ginkgolides in the child’s urine is confirmed in panel C (see
arrows). The most abundant compound was Ginkgolide B,
with a urine concentration of approximately 40 μg mL−1; Gink-
golide A and C were present in concentrations close to 1 and
2 μg mL−1, respectively. Bilobalide was not detectable.
Conclusions
The case described in this paper shows that the poisoning due
to Ginkgo biloba seeds must be considered as a possible clini-
cal event also in European countries, where Asian cuisine has
received a relatively recent popularity. Any introduction of new
dietetic habits requires suitable information to be provided, as
in the case of Ginkgo biloba seeds, which are appreciated also
by children for their good flavour. Unfortunately, particularly
for the youngest children they could represent a risk, as shown
by case reports published in the scientific literature.7,8,10 In
the case described here, poisoning was confirmed by identifying
biomarkers both in blood and urine. Traditionally, 4′-O-methyl-
pyridoxine (MPN) has been considered as the specific bio-
marker for ginkgo seed poisoning, both in blood and urine.
Considering the diﬀerent papers reporting cases of ginkgo seed
poisoning (Table 4), it quite evident the diﬃculty in correlating
the number of seeds ingested with MPN serum concentration;
moreover, the kinetic of MPN in serum and urine after exposure
is complex and shows a significant variability.
The case reported here showed a MPN serum concentration
of 16.5 and 6.2 ng mL−1 after 14 and 20 hours from the
exposure, respectively. These values are below the concen-
trations measured by other authors (usually above 100 ng
mL−1) but, in agreement with our data, Hasegawa et al. (2006)8
Fig. 4 HPLC Chromatograms of a standard solution of 4’-O-methylpyridoxine (MPN) at the concentration of 0.1 µg mL−1 (A), the patient’s serum at
14 h after exposure (B), and at 20 h after exposure (C). All peaks in the chromatogram apart from that of MPN, where present in the blank serum
used for developing the method.
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showed that a concentration of 37 ng mL−1 at 4 hours after the
consumption of 50 ginkgo nuts was enough to induce vomit-
ing and afebrile convulsion in a 2-year-old boy. Moreover,
Kajiyama & Fjii (2002)7 showed a very quick decrease of MPN
concentration in serum: from 360 ng mL−1 after 9 hours from
the exposure to <15 ng mL−1 one hour later, indicating that
the timing of sample collection could be critical in detecting
the biomarker.
The variability observed in the MPN serum concentration
could be justified (at least partially) by the significant diﬀer-
ence in MPN content measured in ginkgo seeds
(172.8–404.2 μg g−1 dry weight), supporting also data reported
by diﬀerent authors where the number of seeds necessary to
produce fatalities varied from 15 and 574.7 According to the
case described here, low values of MPN serum concentration
can also be responsible for convulsions and adverse eﬀects
and it is known that MPN toxicity can be modulated by several
factors, such as the patient’s nutritional state, where a particu-
lar role can be played by the pyridoxine storage.7
In contrast to some previous papers, MPN was not detect-
able in the child’s urine, but the ginkgo poisoning was con-
firmed by the identification of ginkgolide terpenic lactones,
which are considered biomarkers for the acute consumption
of Ginkgo biloba derivatives.20
Fig. 5 HPLC/MS of ginkgolide terpene lactones. Panel A = SIM chromatograms of a standard mixture containing ginkgolide A, ginkgolide B, ginkgo-
lide C and bilobalide at the concentration for each analyte of 10 µg mL−1; panel B = SIM and TIC chromatograms of the “blank” urine; panel C = SIM
and TIC chromatograms of the patient’s urine (C).
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The correct diagnosis of ginkgo poisoning, is important for
suitable treatment of the patient (which usually require
vitamin B6 administration
7,8,10,23), and to avoid fatalities, so
that the identification of MPN in serum or urine could be very
useful. A sensitive method for the detection of this biomarker
was optimized and validated specifically for the cases of
poisoning by ginkgo seeds. We showed in this study that
poisoning can be severe also when the level of MPN in urine is
not detectable; in these cases, the identification and semi-
quantitation of ginkgolide terpene lactones in urine provides a
valuable tool in confirming the acute consumption of ginkgo
seeds. Moreover, we observed that the ratio between the three
main ginkgolides (A : B : C) was approximately 1 : 40 : 2. The
relative abundance of excreted ginkgolides was diﬀerent from
that observed by Dew et al. (2014),20 where ginkgolide A was
the most abundant terpenoid in urine after the consumption
of leaf extract (109% of quantity administered). If confirmed
by other studies, this specific ginkgolide relative abundance in
urine, associated with the absence/very low quantity of biloba-
lide, could be also used to distinguish between poisoning due
to ginkgo leaves and that from seeds. Finally, the case
described indicates that population, family doctors, and au-
thorities need to be informed on the specific risk deriving
from food containing ginkgo, taking also into consideration
the increasing diﬀusion worldwide of oriental cuisine.
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